Construction of a novel inflammatory-related prognostic signature of acute myelocytic leukemia based on conjoint analysis of single-cell and bulk RNA sequencing

IntroductionThe prognostic management of acute myeloid leukemia (AML) remains a challenge for clinicians. This study aims to construct a novel risk model for AML patient through comprehensive analysis of scRNA and bulk RNA data to optimize the precise treatment strategies for patients and improve pr...

Full description

Saved in:
Bibliographic Details
Main Authors: Yongfen Huang, Ping Yi, Yixuan Wang, Lingling Wang, Yongqin Cao, Jingbo Lu, Kun Fang, Yuexin Cheng, Yuqing Miao
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1565954/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850215545334398976
author Yongfen Huang
Ping Yi
Ping Yi
Yixuan Wang
Lingling Wang
Yongqin Cao
Jingbo Lu
Kun Fang
Kun Fang
Yuexin Cheng
Yuqing Miao
Yuqing Miao
author_facet Yongfen Huang
Ping Yi
Ping Yi
Yixuan Wang
Lingling Wang
Yongqin Cao
Jingbo Lu
Kun Fang
Kun Fang
Yuexin Cheng
Yuqing Miao
Yuqing Miao
author_sort Yongfen Huang
collection DOAJ
description IntroductionThe prognostic management of acute myeloid leukemia (AML) remains a challenge for clinicians. This study aims to construct a novel risk model for AML patient through comprehensive analysis of scRNA and bulk RNA data to optimize the precise treatment strategies for patients and improve prognosis.Methods and ResultsscRNA-seq classified cells into nine clusters, including Bcells, erythrocyte, granulocyte-macrophage progenitor (GMP), hematopoietic stem cell progenitors (HSC/Prog), monocyte/macrophagocyte (Mono/Macro), myelocyte, neutrophils, plasma, and T/NK cells. Functional analysis demonstrated the important role of inflammation immune response in the pathogenesis of AML, and the leukocyte transendothelial migration and adhesion in the process of inflammation should be noticed. ssGSEA method identified four core cells including GMP, HSC/Prog, Mono/Macro, and myelocyte for subsequent analysis, which contains 1,594 marker genes. Furthermore, we identified AML-associated genes (2,067genes) and DEGs (1,010genes) between AML patients and controls usingGSE114868dataset. After performing intersection, univariate Cox, and LASSO analysis, we obtained a prognostic model based on the expression levels of five signature genes, namely, CALR, KDM1A, SUCNR1, TMEM220, and ADM. The prognostic model was then validated by two external datasets. Patients with high-risk scores are predisposed to experience poor overall survival. Further GSEA analysis of risk-model-related genes revealed the significant differences in inflammatory response between high-and low-risk groups.ConclusionIn conclusion, we constructed an inflammation related risk model using internal scRNA data and external bulk RNA data, which can accurately distinguish survival outcomes in AML patients.
format Article
id doaj-art-d77b3999b96c4c7e9cc5da9a85f9d933
institution OA Journals
issn 1664-3224
language English
publishDate 2025-06-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj-art-d77b3999b96c4c7e9cc5da9a85f9d9332025-08-20T02:08:35ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-06-011610.3389/fimmu.2025.15659541565954Construction of a novel inflammatory-related prognostic signature of acute myelocytic leukemia based on conjoint analysis of single-cell and bulk RNA sequencingYongfen Huang0Ping Yi1Ping Yi2Yixuan Wang3Lingling Wang4Yongqin Cao5Jingbo Lu6Kun Fang7Kun Fang8Yuexin Cheng9Yuqing Miao10Yuqing Miao11Department of Hematology, Yancheng No.1 People’s Hospital, Yancheng, ChinaDepartment of Scientific Research Project, Wuhan Kindstar Medical Laboratory Co., Ltd., Wuhan, ChinaKindstar Global Precision Medicine Institute, Wuhan, ChinaYancheng Clinical College, Xuzhou Medical University, Yancheng, ChinaDepartment of Hematology, Yancheng No.1 People’s Hospital, Yancheng, ChinaDepartment of Hematology, Yancheng No.1 People’s Hospital, Yancheng, ChinaDepartment of Hematology, Yancheng No.1 People’s Hospital, Yancheng, ChinaDepartment of Scientific Research Project, Wuhan Kindstar Medical Laboratory Co., Ltd., Wuhan, ChinaKindstar Global Precision Medicine Institute, Wuhan, ChinaDepartment of Hematology, Yancheng No.1 People’s Hospital, Yancheng, ChinaDepartment of Hematology, Yancheng No.1 People’s Hospital, Yancheng, ChinaYancheng Clinical College, Xuzhou Medical University, Yancheng, ChinaIntroductionThe prognostic management of acute myeloid leukemia (AML) remains a challenge for clinicians. This study aims to construct a novel risk model for AML patient through comprehensive analysis of scRNA and bulk RNA data to optimize the precise treatment strategies for patients and improve prognosis.Methods and ResultsscRNA-seq classified cells into nine clusters, including Bcells, erythrocyte, granulocyte-macrophage progenitor (GMP), hematopoietic stem cell progenitors (HSC/Prog), monocyte/macrophagocyte (Mono/Macro), myelocyte, neutrophils, plasma, and T/NK cells. Functional analysis demonstrated the important role of inflammation immune response in the pathogenesis of AML, and the leukocyte transendothelial migration and adhesion in the process of inflammation should be noticed. ssGSEA method identified four core cells including GMP, HSC/Prog, Mono/Macro, and myelocyte for subsequent analysis, which contains 1,594 marker genes. Furthermore, we identified AML-associated genes (2,067genes) and DEGs (1,010genes) between AML patients and controls usingGSE114868dataset. After performing intersection, univariate Cox, and LASSO analysis, we obtained a prognostic model based on the expression levels of five signature genes, namely, CALR, KDM1A, SUCNR1, TMEM220, and ADM. The prognostic model was then validated by two external datasets. Patients with high-risk scores are predisposed to experience poor overall survival. Further GSEA analysis of risk-model-related genes revealed the significant differences in inflammatory response between high-and low-risk groups.ConclusionIn conclusion, we constructed an inflammation related risk model using internal scRNA data and external bulk RNA data, which can accurately distinguish survival outcomes in AML patients.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1565954/fullacute myeloid leukemiaScRNA-seqbulk RNA-seqprognostic signatureinflammation
spellingShingle Yongfen Huang
Ping Yi
Ping Yi
Yixuan Wang
Lingling Wang
Yongqin Cao
Jingbo Lu
Kun Fang
Kun Fang
Yuexin Cheng
Yuqing Miao
Yuqing Miao
Construction of a novel inflammatory-related prognostic signature of acute myelocytic leukemia based on conjoint analysis of single-cell and bulk RNA sequencing
Frontiers in Immunology
acute myeloid leukemia
ScRNA-seq
bulk RNA-seq
prognostic signature
inflammation
title Construction of a novel inflammatory-related prognostic signature of acute myelocytic leukemia based on conjoint analysis of single-cell and bulk RNA sequencing
title_full Construction of a novel inflammatory-related prognostic signature of acute myelocytic leukemia based on conjoint analysis of single-cell and bulk RNA sequencing
title_fullStr Construction of a novel inflammatory-related prognostic signature of acute myelocytic leukemia based on conjoint analysis of single-cell and bulk RNA sequencing
title_full_unstemmed Construction of a novel inflammatory-related prognostic signature of acute myelocytic leukemia based on conjoint analysis of single-cell and bulk RNA sequencing
title_short Construction of a novel inflammatory-related prognostic signature of acute myelocytic leukemia based on conjoint analysis of single-cell and bulk RNA sequencing
title_sort construction of a novel inflammatory related prognostic signature of acute myelocytic leukemia based on conjoint analysis of single cell and bulk rna sequencing
topic acute myeloid leukemia
ScRNA-seq
bulk RNA-seq
prognostic signature
inflammation
url https://www.frontiersin.org/articles/10.3389/fimmu.2025.1565954/full
work_keys_str_mv AT yongfenhuang constructionofanovelinflammatoryrelatedprognosticsignatureofacutemyelocyticleukemiabasedonconjointanalysisofsinglecellandbulkrnasequencing
AT pingyi constructionofanovelinflammatoryrelatedprognosticsignatureofacutemyelocyticleukemiabasedonconjointanalysisofsinglecellandbulkrnasequencing
AT pingyi constructionofanovelinflammatoryrelatedprognosticsignatureofacutemyelocyticleukemiabasedonconjointanalysisofsinglecellandbulkrnasequencing
AT yixuanwang constructionofanovelinflammatoryrelatedprognosticsignatureofacutemyelocyticleukemiabasedonconjointanalysisofsinglecellandbulkrnasequencing
AT linglingwang constructionofanovelinflammatoryrelatedprognosticsignatureofacutemyelocyticleukemiabasedonconjointanalysisofsinglecellandbulkrnasequencing
AT yongqincao constructionofanovelinflammatoryrelatedprognosticsignatureofacutemyelocyticleukemiabasedonconjointanalysisofsinglecellandbulkrnasequencing
AT jingbolu constructionofanovelinflammatoryrelatedprognosticsignatureofacutemyelocyticleukemiabasedonconjointanalysisofsinglecellandbulkrnasequencing
AT kunfang constructionofanovelinflammatoryrelatedprognosticsignatureofacutemyelocyticleukemiabasedonconjointanalysisofsinglecellandbulkrnasequencing
AT kunfang constructionofanovelinflammatoryrelatedprognosticsignatureofacutemyelocyticleukemiabasedonconjointanalysisofsinglecellandbulkrnasequencing
AT yuexincheng constructionofanovelinflammatoryrelatedprognosticsignatureofacutemyelocyticleukemiabasedonconjointanalysisofsinglecellandbulkrnasequencing
AT yuqingmiao constructionofanovelinflammatoryrelatedprognosticsignatureofacutemyelocyticleukemiabasedonconjointanalysisofsinglecellandbulkrnasequencing
AT yuqingmiao constructionofanovelinflammatoryrelatedprognosticsignatureofacutemyelocyticleukemiabasedonconjointanalysisofsinglecellandbulkrnasequencing